Quazinone

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Quazinone
Quazinone structure.png
Systematic (IUPAC) name
(3R)-6-chloro-3-methyl-5,10-dihydroimidazo[2,1-b]quinazolin-2(3H)-one
Clinical data
Legal status Prescription only
Routes Oral
Identifiers
CAS number 70018-51-8
ATC code None
PubChem CID 6603980
ChemSpider 5036286
UNII D1Q7F6C2FP YesY
KEGG D05668
Synonyms Ro 13-6438
Chemical data
Formula C11H10ClN3O 
Mol. mass 235.67 g/mol

Quazinone (Dozonone) is a cardiotonic and vasodilator drug which was developed and marketed in the 1980s for the treatment of heart disease.[1][2][3][4][5] It acts as a selective PDE3 inhibitor.[6][7] It is no longer available.[1]

Synthesis[edit]

Quazinone.png[8]

See also[edit]

References[edit]

  1. ^ a b David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9. 
  2. ^ Eigenmann R, Gerold M, Holck M (1984). "Cardiovascular profile of Ro 13-6438, a novel positive inotropic agent with vasodilating properties". Journal of Cardiovascular Pharmacology 6 (3): 511–9. doi:10.1097/00005344-198405000-00021. PMID 6202980. 
  3. ^ Holck M, Thorens S, Muggli R, Eigenmann R (1984). "Studies on the mechanism of positive inotropic activity of Ro 13-6438, a structurally novel cardiotonic agent with vasodilating properties". Journal of Cardiovascular Pharmacology 6 (3): 520–30. PMID 6202981. 
  4. ^ Belz GG, Stern HC, Butzer R (1985). "Dose-response following single administrations of a new cardiac performance enhancer RO 13-6438 in normal volunteers". Journal of Cardiovascular Pharmacology 7 (1): 86–90. doi:10.1097/00005344-198501000-00014. PMID 2580156. 
  5. ^ Daly PA, Chatterjee K, Viquerat CE, et al. (June 1985). "RO13-6438, a new inotrope-vasodilator: systemic and coronary hemodynamic effects in congestive heart failure". The American Journal of Cardiology 55 (13 Pt 1): 1539–44. doi:10.1016/0002-9149(85)90969-5. PMID 4003296. 
  6. ^ Osinski MT, Schrör K (August 2000). "Inhibition of platelet-derived growth factor-induced mitogenesis by phosphodiesterase 3 inhibitors: role of protein kinase A in vascular smooth muscle cell mitogenesis". Biochemical Pharmacology 60 (3): 381–7. doi:10.1016/S0006-2952(00)00328-2. PMID 10856433. 
  7. ^ Denis D, Riendeau D (February 1999). "Phosphodiesterase 4-dependent regulation of cyclic AMP levels and leukotriene B4 biosynthesis in human polymorphonuclear leukocytes". European Journal of Pharmacology 367 (2-3): 343–50. doi:10.1016/S0014-2999(98)00987-X. PMID 10079010. 
  8. ^ Chodnekar, M. S.; Kaiser, A.; 1981, U.S. Patent 4,256,748